The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK

Journal of the Neurological Sciences

Volumn 191, Issue 1-2, 2001, Pages 95-102

  Tavakoli, Manouche ^a   Malek, M ^a  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

ALS; Cost effectiveness; Cost utility; Markov models; Riluzole

Indexed keywords

RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; HEALTH STATUS; HUMAN; PRIORITY JOURNAL; PROBABILITY; STANDARD; TECHNIQUE; UNITED KINGDOM;

AMYOTROPHIC LATERAL SCLEROSIS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; FORECASTING; GREAT BRITAIN; HEALTH STATUS; HUMANS; MARKOV CHAINS; MODELS, ECONOMETRIC; MULTICENTER STUDIES; NEUROPROTECTIVE AGENTS; PALLIATIVE CARE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; RILUZOLE; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; VALUE OF LIFE;

EID: 0035886399     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(01)00618-9     Document Type: Article

References (47)

1. Modelling the long-term cost-effectiveness of riluzole for the treatment of amyotrophic lateral sclerosis
2. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole
3. Palliative care in amyotrophic lateral sclerosis
4. Amyotrophic lateral sclerosis: Recent advances in understanding disease mechanisms
5. The Scottish motor neuron disease register: A Prospective study of adult onset motor neuron disease in Scotland: Methodology, demography, and clinical features of incident cases in 1989
6. Amyotrophic lateral sclerosis. Current and future treatment strategies
7. Clinical trials in ALS: Measurement and natural history
8. Amyotrophic lateral sclerosis: Part 1. Clinical features, pathology, and ethical issues in management
9. Onset, natural history and outcome in idiopathic adult motor neuron disease
10. Amyotrophic lateral sclerosis: Communication status and survival with ventilatory support
11. Survival prediction in amyotrophic lateral sclerosis
12. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction
13. Economic burden of amyotrophic lateral sclerosis in the United Kingdom
14. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis
15. ALS
16. What do we really know about amyotrophic lateral sclerosis?
17. Motor neurone disease
18. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis
19. A controlled trial of riluzole in amyotrophic lateral sclerosis
20. 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission: I. Anticonvulsant properties
21. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
22. 'Quick and clean': Authoritative health technology assessment for local health care contracting
23. Markov models in medical decision making: A practical guide
24. An introduction to Markov modelling for economic evaluation
25. Cost effectiveness of screening for eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age
26. A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions
27. The Markov process in medical prognosis
28. Utility approach to measuring health-related quality of life
29. Application of multi-attribute utility theory to measure social preferences for health states
30. Patients' health related quality of life and utilities associated with different stages of amyotrophic lateral sclerosis
31. Modeling valuations for EuroQol health states
32. Visual analog scales, standard gambles, and relative risk aversion
33. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2
34. Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples
35. Measurement of health state utilities for economic appraisal: A review
36. Discounting and health benefits
37. Discounting discounting
38. Cost effectiveness of riluzole in amyotrophic lateral sclerosis
39. Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis
40. The clinical effectiveness and cost effectiveness or riluzole for motor neuron disease - An update